AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03910712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.
Study NCT03910712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
Study NCT03910712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
Study NCT03910712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor
Description: The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
Study NCT03910712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase inhibitor
Description: The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
Study NCT01002456 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Level 1: (provide site-specifi information)
Description: provide site-specific information on non-adherence to guideline
Study NCT01002456 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Level 2 (Provide site- and patient-specific information)
Description: provide site-specific information on non-adherence to guideline as well as list of patients with non-adherent prescriptions
Study NCT03491709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-EGFR monoclonal antibody
Description: Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection
Study NCT03491709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab injection
Description: Cetuximab injection
Study NCT04213924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl 0.5 % in 10 ml and 2 % lidocaine in 10 ml
Description: Erector spinae plane block, 30 min before the ESWL procedure.
Study NCT04213924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously
Description: 5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously, 30 min before the ESWL procedure.
Study NCT03236051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia
Description: Multimodal analgesia is the name of a procedure or program. Multimodal analgesia doesn't mean different interventions are used. Patients in this group need receive this analgesia program (procedure) instead of one analgesic drug or technology. The program consists of incision infiltration with ropivacaine, intravenous injection of parecoxib, and oral administration of oxycodone/paracetamol mixture.
Study NCT03236051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCIA analgesia
Description: PCIA analgesia:patient-controlled intravenous analgesia with tramadol.
Study NCT04058951 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High Animal Protein Diet (HAPD)
Description: A diet containing 2,0 g protein per kilo body weight per day from primarily animal origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on beef isolate.
Study NCT04058951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Plant Protein Diet (HPPD)
Description: A diet containing 2,0 g protein per kilo body weight per day exclusively from plant origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on soy isolate.
Study NCT05138523 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Sofosdac®
Description: Once daily fixed-dose combination of 400 mg Sofosbuvir and 60 mg Daclatasvir
Study NCT00559442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude Exposure:
Description: rapid ascent to Margherita Hut (4559 m) within 24 h
Study NCT00833911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Once A Day
Study NCT01399190 — intervention group
Intervention type: BIOLOGICAL
Intervention: Bevacizumab
Description: Bevacizumab administered according to prescribing information and normal clinical practice.
Study NCT01399190 — intervention group
Intervention type: BIOLOGICAL
Intervention: Capecitabine
Description: Capecitabine administered according to prescribing information and normal clinical practice.
Study NCT01399190 — intervention group
Intervention type: DRUG
Intervention: Oxaliplatin
Description: Capecitabine administered according to prescribing information and normal clinical practice.
Study NCT00963833 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Patients under daily life treatment receiving Betaferon according to local product information.
Study NCT00059839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00059839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given by mouth
Study NCT04327804 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Odd/Even birth year intervention groups
Description: The nostril used and order of testing will be different in each arm.
Study NCT04258800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music during colonoscopy
Description: Music during colonoscopy
Study NCT00059839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV and intrathecally
Study NCT00059839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given by mouth
Study NCT00059839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine sulfate
Description: Given IV
Study NCT00059839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT05873946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: intraoperative ultrasound
Description: Use of 2D non-navigated intraoperative ultrasound as an operative adjunct
Study NCT02709525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Study NCT02709525 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01693081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VR040/Aspirair® inhaler
Description: Dry Powder inhaled apomorphine
Study NCT01693081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04377828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pigment laser
Description: one to two session of pigment laser (532 nm)
Study NCT01137955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin 400mg orally three times a day for 10 days total
Study NCT01137955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally three times a day for 10 days total
Study NCT01207596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Oral hydromorphone extended release, once daily
Study NCT03150316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treat Regimen
Description: CKD-581(investigational Drug): on days 1, 8, 15 of repeated 28day cycles Lenalidomide: on days 1\~21 of repeated 28 day cycles Dexamethasone: administrated once weekly every 28day cycles
Study NCT01494454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/BCP/TSRH® or rhBMP-2/BCP/CD HORIZON® Spinal System
Description: rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, either the TSRH® Spinal System or CD HORIZON® Spinal System.
Study NCT01494454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft/TSRH® or autograft/CD HORIZON® Spinal System.
Description: Either the TSRH® Spinal System or the CD HORIZON® Spinal System with autogenous bone taken from the patient's iliac crest.
Study NCT01290705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High exercise therapy
Study NCT01290705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low exercise therapy
Study NCT01240083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thetaburst Stimulation
Description: Thetaburst stimulation: continuous TBS over the right DLPFC, followed by intermitted TBS over the left DLPFC, each with 50 Hz, together 1200 stimuli (80% motorthreshold)
Study NCT01240083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency rTMS
Description: Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC (110% motor threshold)followed by 1000 stimuli of 10 Hz over the left DLPFC (110% motorthreshold)
Study NCT01240083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Stimulation
Description: Sham Stimulation (Sham coil):right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
Study NCT03953508 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cigarette flavor type
Description: Participants will smoke several puffs (each) of a menthol Camel Crush and several puffs of a non-menthol Camel Crush cigarette.
Study NCT00621894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGD-4665
Description: LGD-4665 Thrombopoietin mimetic
Study NCT00621894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00165633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menatetrenone
Description: 45 mg capsule, orally, three times a day, after meals.
Study NCT00165633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menatetrenone
Description: 90 mg capsule, orally, three times a day, after meals.
Study NCT00165633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, orally, three times a day, after meals.
Study NCT01584154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryoablation
Description: cryoablation with an 8mm-tip catheter
Study NCT01584154 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: radiofrequency ablation with a 4mm-tip catheter
Study NCT02231125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan potassium tablet 100mg/time, once /day plus Huangkui Capsule dummy 2.5g/time, thrice /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
Study NCT02231125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abelmoschus manihot
Description: Huangkui Capsule 2.5g/time, thrice /day plus Losartan potassium tablet dummy 100mg/time, once /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
Study NCT04287842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Desflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest.
Study NCT04287842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Desflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
Study NCT04287842 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac arrest
Description: Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
Study NCT04287842 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac arrest
Description: Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
Study NCT03678103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00029
Description: Noninvasive pulse oximeter sensor
Study NCT00482924 — intervention group
Intervention type: OTHER
Intervention: Lifestyle intervention
Description: Regular sports and dietary advices. Controlled by analysis of laboratory parameters, BMI change and performance diagnostics. No drugs included so far.
Study NCT02315677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Intubation with nasal RAE endotracheal tube
Description: A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the standard nasal RAE endotracheal tube with bevel facing leftward.
Study NCT02315677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Intubation with Parker Flex-Tip endotracheal tube
Description: A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the Parker Flex-Tip endotracheal tube with the bevel facing posteriorly.
Study NCT01821378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 20 mg once daily
Study NCT01821378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lurasidone
Description: Lurasidone 20 mg once daily
Study NCT01821378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2
Description: Lurasidone 80 mg once daily
Study NCT01821378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2
Description: Lurasidone 80 mg once daily
Study NCT01821378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once Daily
Study NCT01821378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once Daily
Study NCT00930514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab subcutaneous injection at 1400 mg dose level, administered every 2 or 3 months.
Study NCT00930514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab subcutaneous injection at 800 mg/m\^2 dose level, administered every 2 or 3 months.
Study NCT00930514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab subcutaneous injection 625 mg/m\^2 administered every 2 or 3 months.
Study NCT00930514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab intravenous infusion 375 milligram per square meter (mg/m\^2) administered every 2 or 3 months.
Study NCT00930514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab subcutaneous injection 375 mg/m\^2 administered every 2 or 3 months.
Study NCT02563093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative
Description: 0.5 mL, Intramuscular (IM)
Study NCT02563093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation
Description: 0.1 mL, Intradermal
Study NCT02563093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative
Description: 0.5 mL, Intramuscular
Study NCT02563093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High-Dose vaccine, 2015-2016 formulation
Description: 0.5 mL, Intramuscular
Study NCT01158651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 (Everolimus)
Description: If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment course lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).~You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection.
Study NCT03296462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip external rotation exercise
Description: Standardised HER exercise training by physiotherapist (plus video recording of exercises)
Study NCT03296462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise
Description: Standardised PFM exercise training by physiotherapist (plus video recording of exercises)
Study NCT03296462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle exercise
Description: Standardised PFM exercise training by physiotherapist (plus video recording of exercises)
Study NCT01264367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine
Description: 30mg,QD
Study NCT01264367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clevudine + Peg-interferon
Description: 30mg, QD(for 24 weeks) + 180mcg,QW(for 24 weeks)
Study NCT03480256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic gastric cancer
Study NCT03643120 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative interview
Description: Explorative study of gender dysphoria.
Study NCT01969825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage
Study NCT05961280 — intervention group
Intervention type: PROCEDURE
Intervention: Mastectomy with sentinel lymph node biopsy
Study NCT04540133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone 0.5mg/5ml solution
Description: Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution three times a day for 4 weeks and expectorate
Study NCT04540133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone 0.5mg/5ml solution in Mucolox™
Description: Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution in Mucolox™ three times a day for 4 weeks and expectorate
Study NCT01717963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone intramuscular suspension
Description: A standard dosage of 380 mg / month of naltrexone intramuscular suspension will be administered
Study NCT01717963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine-naloxone
Description: Buprenorphine-naloxone is administered daily and provided in accordance with existing guidelines for OMT in Norway (treatment-as-usual).
Study NCT01875822 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super-Curcumin
Description: The investigators are comparing the effects of the two dosages of Super-Curcumin@ capsules in the sample of subjects diagnosed as DSM IV-R schizophrenia
Study NCT02217189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc sulfate
Description: The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
Study NCT03272542 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic: soluble corn fiber
Description: prebiotic
Study NCT03272542 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: maltodextrin
Description: placebo
Study NCT04580862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-surgical endodontic retreatment in single visit
Description: Full medical and dental history using a schematic dental chart, will be obtained from all patients treated during this study.
Study NCT04580862 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical endodontic retreatment in single visit
Description: Full medical and dental history using a schematic dental chart, will be obtained from all patients treated during this study.
Study NCT04845360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pressure transducer (PSL-200GL, Kyowa Electronic Instrument Co. Ltd., Japan)
Description: The device was fixed on the patient's skin with Scotch™ tape, along with an adjustable belt with a small button to give suitable pressure on the transducer.